Menu

Category Archives for "News"

Abattis Provides Update on Trading Halt and Corporate Developments

Nov 8, 2019    |    Abattis Bioceuticals
VANCOUVER, BRITISH COLUMBIA / Nov 8th, 2019 / Abattis Bioceuticals Corp (the “Company” or “Abattis“) (CSE:ATT) (OTC:ATTBF) November 8, 2019 / Abattis Bioceuticals Corp. (the “Company” or “Abattis“) (CSE:ATT) (OTC:ATTBF) announces the following updates on recent developments related to Abattis since the trading of the Company’s common shares on the Canadian Stock Exchange (the “CSE”) was halted on February 4, 2019 (the “Halt”).

Read More

Abattis Announces Successful Closing of Pro Natura Acquisition

May 21, 2019    |    Abattis Bioceuticals
VANCOUVER, BRITISH COLUMBIA / May 21st, 2019 / Abattis Bioceuticals Corp (the “Company” or “Abattis“) (CSE:ATT) (OTC:ATTBF) is pleased to announce that, further to its news release dated April 2nd, 2019, the Company’s wholly-owned subsidiary, 1185277 B.C. Ltd. (the “Acquisition Subsidiary”) has successfully closed the acquisition (the “Acquisition”) of Pro Natura BV (“Pro Natura”).

Read More

Abattis Removed from BCSC Temporary Order

VANCOUVER, BRITISH COLUMBIA / January 17, 2019 / Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce that the temporary order from the British Columbia Securities Commission (“BCSC”), issued on November 26, 2018 (the “Order”), has not been extended against Abattis.

Read More

Abattis Enters into Definitive Share Exchange Agreement with Nutrivida

Abattis Enters into Definitive Share Exchange Agreement with Nutrivida January 10, 2019    |    Abattis Bioceuticals VANCOUVER, BRITISH COLUMBIA / January 10, 2019 / Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce that, further to its new release dated December 7, 2018, the Company has entered into a definitive share […]

Read More
1 2 3 11